Howard Stern TRT: How a Regular Patient Would Get Access

What Howard Stern Has Said About TRT

Howard Stern has addressed his testosterone use on air and in interviews on multiple occasions, describing it as a medically supervised part of his overall health maintenance. He has framed TRT not as a performance-enhancement strategy but as corrective therapy for declining hormone levels that come with age.

What He Has Publicly Stated

Stern has mentioned testosterone therapy alongside other health interventions he discusses candidly on The Howard Stern Show, including dietary changes and regular medical monitoring. He has described feeling markedly better in terms of energy and mental clarity after starting the therapy. These statements are self-reported and have not been independently verified through medical records, so they should be treated as first-person disclosures rather than confirmed diagnoses.

Why This Matters Clinically

Stern's public disclosure reflects a pattern seen across the broader male population. Total testosterone levels decline roughly 1 to 2 percent per year after age 30, according to data from the Massachusetts Male Aging Study [1]. By the time a man reaches his 60s, a meaningful proportion will meet biochemical criteria for hypogonadism. Stern, born in 1954, is squarely in the age range where low testosterone becomes clinically common.

Inference vs. Confirmed Fact

Stern has not published lab values or prescription details. Any clinical specifics about his regimen are inferred from his own statements. The pathway described in the rest of this article is how a standard patient without Stern's celebrity status or resources would go through the same process.

What Is TRT and Who Qualifies

Testosterone replacement therapy is FDA-approved treatment for hypogonadism, defined as a clinical syndrome combining low serum testosterone and symptoms attributable to that deficiency [2]. The Food and Drug Administration approved testosterone products for this indication starting with testosterone cypionate decades ago, and the current labeling requires documented low testosterone plus symptoms before prescribing [3].

The Two-Test Rule

The American Urological Association 2018 guideline on testosterone deficiency states that clinicians "should not diagnose testosterone deficiency in men with only one testosterone value in the low range without a confirmatory test" [4]. Two morning fasting measurements of total testosterone below 300 ng/dL, taken on separate days, are the standard threshold. A single low value can result from acute illness, stress, or timing (testosterone peaks between 7 and 10 a.m.).

Symptoms That Prompt Testing

Biochemical criteria alone are not sufficient. The AUA guideline lists the following symptoms as grounds for evaluation:

• Decreased libido
• Erectile dysfunction
• Reduced energy and fatigue
• Depressed mood
• Loss of muscle mass and increased body fat
• Decreased bone mineral density
• Hot flashes or sweats

Patients presenting with three or more of these symptoms alongside a BMI <35 and no recent major illness are reasonable candidates for the two-sample morning testosterone draw.

Free vs. Total Testosterone

Total testosterone is the standard screen. Free testosterone becomes relevant when sex hormone-binding globulin (SHBG) is elevated, which occurs in obesity, liver disease, and with aging. The Endocrine Society 2010 clinical practice guideline recommends measuring free testosterone when total testosterone is borderline (300 to 400 ng/dL) and symptoms are present [5]. Calculated free testosterone using the Vermeulen equation is preferred over direct immunoassay, which has poor accuracy at low concentrations.

The Step-by-Step Access Pathway

Getting TRT as a standard patient involves six sequential steps. Each has a defined timeline and decision point.

Step 1: Primary Care or Telehealth Intake (Week 1)

A patient starts by scheduling a visit with a primary care physician, an endocrinologist, a urologist, or a licensed telehealth TRT provider. At intake, the clinician collects a full symptom history using a validated questionnaire such as the Androgen Deficiency in Aging Males (ADAM) questionnaire or the Aging Males' Symptoms (AMS) scale [6]. A positive ADAM screen (any "yes" to questions 1 or 7, or any three other questions) warrants lab work.

Step 2: Baseline Laboratory Panel (Week 1 to 2)

The standard pre-treatment panel includes:

• Total testosterone (two morning draws, ideally at least 48 hours apart)
• Free testosterone (calculated)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Complete blood count with hematocrit
• PSA (in men over 40)
• Comprehensive metabolic panel
• Lipid panel
• Estradiol (E2)
• Prolactin (if secondary hypogonadism is suspected)

Turnaround for most commercial labs (Quest, LabCorp) is 24 to 72 hours.

Step 3: Diagnosis Confirmation (Week 2 to 3)

If both testosterone values are below 300 ng/dL and symptoms align, the clinician confirms the diagnosis. Elevated LH and FSH point to primary hypogonadism (testicular failure). Low or normal LH and FSH with low testosterone indicates secondary hypogonadism, which warrants pituitary MRI to rule out a prolactinoma or other structural lesion before prescribing [5].

Step 4: Treatment Selection (Week 3)

The clinician selects a delivery method based on patient preference, insurance, and clinical factors:

| Formulation | Typical Dose | Frequency | Notes | |---|---|---|---| | Testosterone cypionate (IM) | 100 to 200 mg | Every 1 to 2 weeks | Most common; can self-inject | | Testosterone enanthate (IM) | 100 to 200 mg | Every 1 to 2 weeks | Interchangeable with cypionate | | Testosterone undecanoate (IM) | 750 mg | Every 10 weeks | Requires clinic administration; Aveed | | Testosterone gel 1% (AndroGel) | 50 to 100 mg/day | Daily | Transference risk to partners/children | | Testosterone patch | 4 mg/day | Daily | Skin irritation common | | Testosterone pellets (Testopel) | 150 to 450 mg | Every 3 to 6 months | Subcutaneous; requires minor procedure |

FDA-approved testosterone products and their labeled doses are listed in the FDA drug database [3]. Testosterone cypionate injected intramuscularly at 100 mg every week produces steadier serum levels than the traditional every-two-week protocol, which causes peaks and troughs that correlate with symptom fluctuation.

Step 5: Monitoring at 6 to 12 Weeks

The Endocrine Society guideline recommends checking testosterone levels 3 to 6 months after starting therapy, with the goal of reaching mid-normal range (400 to 700 ng/dL) [5]. Hematocrit must be checked because testosterone stimulates erythropoiesis. If hematocrit exceeds 54 percent, the dose is reduced or dosing interval extended. PSA is rechecked at 3 to 6 months; a rise of more than 1.4 ng/mL above baseline within any 12-month period warrants urologic referral [5].

Step 6: Long-Term Surveillance

Annual monitoring includes hematocrit, PSA, lipids, and a symptom review. Bone mineral density by DEXA scan is recommended at baseline and every 1 to 2 years in men with osteoporosis risk [5]. Fertility counseling is part of long-term care: exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and spermatogenesis. Men who want to preserve fertility should be offered human chorionic gonadotropin (hCG) co-administration or clomiphene citrate as an alternative to direct testosterone therapy [4].

Clinical Evidence Behind TRT

TRT prescribing accelerated after several large trials quantified its benefits and risks in older men. The data are more nuanced than either enthusiasts or critics often present.

The Testosterone Trials (TTrials)

The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled trials enrolling 788 men aged 65 and older with total testosterone below 275 ng/dL [7]. Published in the New England Journal of Medicine in 2016, the sexual function trial showed a statistically significant improvement in sexual desire and erectile function scores (P<0.001). The physical function trial showed modest improvement in walking distance. The vitality trial did not show a statistically significant improvement in energy using the SF-36 vitality subscale [7]. These results inform current clinical expectations: TRT reliably improves sexual function and modestly improves physical performance in hypogonadal older men, but its effect on subjective energy is variable.

Cardiovascular Signal

The TTrials cardiovascular imaging substudy (n=170) found a significantly greater increase in coronary artery noncalcified plaque volume in the testosterone group compared to placebo after one year [8]. The FDA added a warning to all testosterone product labels in 2015 about potential cardiovascular risk, though the agency acknowledged the data were insufficient to determine whether testosterone therapy causes cardiovascular events [3]. The TRAVERSE trial (n=5,204), published in the New England Journal of Medicine in 2023, found testosterone was noninferior to placebo for major adverse cardiovascular events (MACE) over a median 33-month follow-up in men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk [9]. The TRAVERSE data have moderated some of the earlier concern, but cardiovascular history remains a required pre-treatment assessment.

Bone Density Data

A 2017 substudy of the TTrials (n=211) showed that testosterone therapy produced significantly greater increases in volumetric bone mineral density at the spine and hip compared to placebo over 12 months [10]. This finding supports the use of TRT in hypogonadal men with documented osteoporosis or high fracture risk.

Telehealth TRT: What Changed After 2020

The COVID-19 pandemic led the DEA and FDA to expand telehealth prescribing authority. Testosterone is a Schedule III controlled substance under the Controlled Substances Act, which ordinarily requires an in-person examination before prescribing. The DEA's 2020 public health emergency telemedicine exemptions allowed prescribing after a video evaluation without a prior in-person visit [11]. As of early 2025, proposed DEA rules would extend some telehealth prescribing flexibilities for controlled substances, though final rules were still pending. Patients should confirm current DEA telemedicine rules with any telehealth TRT provider before enrollment.

What a Legitimate Telehealth TRT Provider Looks Like

A compliant telehealth TRT provider will:

1. Require two morning testosterone lab draws before prescribing, not just one.
2. Collect a full symptom history and review contraindications (active prostate cancer, hematocrit above 50 percent, uncontrolled heart failure, untreated severe obstructive sleep apnea).
3. Order PSA before prescribing in men over 40.
4. Prescribe only FDA-approved testosterone formulations, not compounded testosterone unless medically justified.
5. Schedule follow-up labs at 6 to 12 weeks and annually thereafter.

Providers who skip baseline labs, offer testosterone based on a symptom questionnaire alone, or pressure patients to start immediately without confirmatory testing are operating outside AUA and Endocrine Society standards.

Contraindications and Who Should Not Use TRT

Not every man with low testosterone is a candidate for treatment. The AUA 2018 guideline lists absolute contraindications including metastatic prostate cancer, breast cancer in men, and a desire to conceive without adjunctive fertility therapy [4]. Relative contraindications include hematocrit above 50 percent, untreated severe obstructive sleep apnea, New York Heart Association class III or IV heart failure, and PSA above 3.4 ng/mL without urologic evaluation [4].

Men with a history of prostate cancer who are in remission may be considered for TRT on a case-by-case basis under careful urologic supervision, but this remains off-label and requires shared decision-making.

Cost and Insurance Coverage

Testosterone cypionate generic injection is among the most affordable TRT options. A 10 mL vial of testosterone cypionate 200 mg/mL costs approximately $30 to $60 at major U.S. Pharmacies with GoodRx pricing. Brand-name gels (AndroGel, Testim) can cost $300 to $500 per month without insurance. Most commercial insurance plans cover testosterone cypionate injections when a confirmed hypogonadism diagnosis (ICD-10 code E29.1 for primary hypogonadism or E23.0 for secondary hypogonadism) is documented with supporting lab values.

Medicare Part D covers FDA-approved testosterone formulations, though prior authorization is common. Patients using telehealth-only plans that prescribe through cash-pay pharmacies will generally pay out of pocket for both the consult and the medication.

What "Normal" Testosterone Actually Means

Reference ranges vary by lab, but most U.S. Laboratories define normal total testosterone as 300 to 1,000 ng/dL in adult men. The AUA guideline notes that "the lower limit of normal for serum testosterone in young healthy men is approximately 300 ng/dL" [4]. A value of 299 ng/dL in a symptomatic 28-year-old is clinically different from the same value in an asymptomatic 70-year-old, which is why guidelines emphasize symptoms alongside biochemistry.

Age-specific reference ranges from the Framingham Heart Study (n=1,203 community-dwelling men) showed median total testosterone of 551 ng/dL in men aged 19 to 40 declining to 432 ng/dL in men aged 70 and older [1]. Using a young-male reference range to diagnose older men produces a higher prevalence estimate, which is one reason published prevalence figures for hypogonadism range widely across studies.

Practical Checklist for a Patient Starting the TRT Pathway

• Schedule a morning appointment (before 10 a.m.) for the first testosterone draw.
• Fast for at least 8 hours before the draw to minimize SHBG fluctuation.
• Avoid acute illness, heavy alcohol use, or significant caloric restriction in the 48 hours before each blood draw.
• Bring a written symptom log covering at least 4 weeks of libido, energy, mood, and sleep.
• Ask the ordering provider whether LH, FSH, prolactin, PSA, and hematocrit are included in the panel.
• Confirm the second morning draw is scheduled within 2 to 4 weeks of the first.
• Ask specifically about fertility plans before any prescription is written.